CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease

T Heliö1, L Halme, M Lappalainen

  • 1Department of Medicine, Helsinki University Hospital, Helsinki, Finland. tiina.helio@hus.fi

Gut
|March 13, 2003
PubMed

Insights

The 1007fs variant of the CARD15/NOD2 gene is linked to Crohn's disease (CD) in Finnish individuals. CARD15 variants also predict disease location and complications in CD patients.

Area of Science:

  • Genetics
  • Gastroenterology
  • Immunology

Background:

  • The caspase activating recruitment domain 15/nucleotide oligomerisation domain 2 (CARD15/NOD2) gene is implicated in Crohn's disease (CD) susceptibility.
  • Specific CARD15 variants have been associated with increased risk of developing CD.

Purpose of the Study:

  • To determine the allele frequencies of CARD15 variants (R702W, G908R, 1007fs) in Finnish patients with inflammatory bowel disease (IBD).
  • To investigate associations between CARD15 variants and familial or complicated forms of CD.

Main Methods:

  • Genotyping for CARD15 variants R702W, G908R, and 1007fs.
  • Study population included sporadic CD patients, familial CD cases, CD patients from mixed IBD families, ulcerative colitis (UC) patients, and healthy controls.

Main Results:

  • The 1007fs variant was significantly more frequent in CD patients (4.8%) compared to controls (1.7%).
  • Familial CD cases showed a higher frequency of the 1007fs allele (10.9%) than non-familial CD.
  • CD patients with at least one CARD15 variant had a higher incidence of ileal disease, stricturing/penetrating complications, and increased need for surgery.

Conclusions:

  • NOD2 gene variant frequencies were lower in the Finnish population compared to other groups.
  • The 1007fs variant is associated with Crohn's disease in this cohort.
  • Presence of CARD15 variants is predictive of ileal disease and complicated CD phenotypes.
Abstract

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...